Other
Publications
Intellectual
Capital Reporting - A Catch-22 or the Future of Corporate Reporting
First
presented at the McMaster University World Congress of Intellectual Capital
in Canada, January 16, 2003. Addresses the question of reporting on the
intellectual capital of publicly traded companies, reviews the current
methods and approaches and envisages the future of corporate reporting.
Knowledge
Management and Business Needs
First presented at the Boston Chapter of the Special Librarian Association
Professional Development Program 2002. A guide to organizations on the
choice of the appropriate knowledge strategies that address their respective
business needs. Explains how the choice of a certain knowledge management
strategy will shape the design of the knowledge base, the knowledge
audit and the overall knowledge management program.
Strategic
Intellectual Asset Management
First presented at the High Performance Pigments Conference, at Florida
in January, 2002. Covers a number of issues relating to the management
of intellectual assets in general, and intellectual property in particular.
Where
Are You on the Intellectual Capital Continuum?
First presented at McMaster University World Congress of Intellectual
Capital, Canada, January, 2002. Presents a brief guide to organizations
that need to figure out where to start in relation to their intellectual
capital management efforts by mapping out all the practices that they
have already implemented on a the “IC Continuum”.
Intellectual
Asset Management: Explained and Expanded
First published in the Advocate (published by Pierce Law) Vol 5, No
1, 2001. Introduces the field of intellectual capital management and
its multi-disciplinary nature, as well as examines the emerging lexicon
in relation to business.
The
Egyptian Pharmaceutical Industry After TRIPS (Trade Related Aspects
of Intellectual Property) - A Practitioners View (Forthcoming)
To be published first in Fordham International Law Journal. Reviews
the competitive landscape of the Egyptian pharmaceutical industry with
emphasis on multinationals and foreign investment in light of the TRIPs
Agreement that extends patent protection to pharmaceuticals.
